CAR-T cell therapeutically technology combines techniques of cell, gene, and immune therapy, which represents the cutting-edge cancer treatment. Based on the success of several clinical trials, CAR-T cell therapy has now become the most popular topic in bio-medical industry.
Acute lymphoblastic leukemia (ALL) is a malignant tumor with abnormal proliferation of B or T cells originating from lymphocytes. Abnormal proliferation of the original cells can accumulate in the bone marrow and inhibit normal hematopoiesis, and can also invade the tissues outside the marrow, such as the meninges, lymph nodes, gonadal glands, and liver. The incidence of leukemia has been investigated in China. The incidence of ALL is about 0.67/10 million. The incidence in oil fields and polluted areas is obviously higher than that in the whole country. ALL childhood (0~9 years old) is the peak of morbidity, accounting for more than 70% of childhood leukemia. ALL accounts for about 20% of adult leukemia in adults. At present, the corresponding treatment scheme based on different biological characteristics of ALL has achieved good curative effect. About 80% of children and 30% of adults can obtain long term disease free survival and have the possibility of cure.
BG-T19 Is my company independent research and development CAR-T The use of the product, the company's core technology TscmRICH . Through a series of cell sorting, activation, amplification, amplification with memory characteristics of stem cells T The ability of anti tumor cells, to ensure the long-term.
The copyright of All Rights Reserved Copyright and Bio gene粤ICP 备17150518号-1